EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0Y3M: Prothena Corporation PLC

03 Jul 2026
LAST:

9.800

CHANGE:
 0.00		OPEN:
10.100		HIGH:
10.100		ASK:
0.000		VOLUME:
1
CHG(%):
0.00		PREV:
9.800		LOW:
9.800		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
03 Jul 2610.10010.1009.8009.8001
02 Jul 269.80010.1009.8009.8002
01 Jul 269.6309.6309.6309.630100
30 Jun 269.84010.0209.8209.820100
29 Jun 2610.06010.0609.8109.850131
26 Jun 269.6909.8109.6909.760353
25 Jun 269.4109.4109.2809.410100
24 Jun 269.6039.6039.6039.603100
23 Jun 269.6189.6308.9709.6301.0K
22 Jun 269.0009.1608.8609.1601.2K

PROFILE

Name:Prothena Corporation PLC
About:Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Address:77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60
Website:https://www.prothena.com

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:7.44 
Price to Sales:26.61 
Price to Book:1.92 
Profit Margin:0.92 
Operating Margin:-16.46 
Return on Assets:-0.29 
Return on Equity:-0.68 
EPS Ratio:1.34 
Revenue:11.79M 
EBITDA:8.14M 
Shares:39.86M 
Market Cap:390.66M 

TECHNICAL INDICATORS

MA5:9.780.2%
MA10:9.651.6%
MA20:9.078.0%
MA50:9.661.5%
MA100:9.641.6%
MA200:9.760.4%
STO9:56.52
STO14:83.78 
RSI14:82.19 
WPR14:-3.13 
MTM14:1.55
ROC14:0.19 
ATR:0.32 
Week High:10.103.1%
Week Low:9.631.8%
Month High:10.103.1%
Month Low:7.890.4%
Year High:11.6719.1%
Year Low:6.1958.3%
Volatility:38.23